APA (7th ed.) Citation

Tas, S. W., Raaphorst, J., Welsing, P. M. J., Laar, J. M. v., Thurlings, R. M., Goekoop, R. J., . . . Present, E. Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Tas, Sander W., et al. Multicentre, 26-week, Open-label Phase 2 Trial of the JAK Inhibitor Filgotinib in Behçet’s Disease, Idiopathic Inflammatory Myopathies and IgG4-related Disease: DRIMID Study Protocol. BMJ Publishing Group.

MLA (9th ed.) Citation

Tas, Sander W., et al. Multicentre, 26-week, Open-label Phase 2 Trial of the JAK Inhibitor Filgotinib in Behçet’s Disease, Idiopathic Inflammatory Myopathies and IgG4-related Disease: DRIMID Study Protocol. BMJ Publishing Group.